| Project/Area Number |
25870760
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General medical chemistry
Respiratory surgery
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 転移 / Eph / ephrin / ADAM / がん |
|---|
| Outline of Final Research Achievements |
It has been reported that overexpression of ephrin-A1 is positively correlated with prognosis in various cancers such as hepatocellular carcinoma. However, the detailed function remains unclear. Therefore, I focused on metastasis that get worse their prognosis in cancer patients and analyzed functions of ephrin-A1 in lung metastasis. I found that ADAM12 identified as a proteinase against ephrin-A1, cleaved ephrin-A1 in primary tumors, and the the serum level is increased. Activated EphA2 by cleaved ephrin-A1 is immediately endocytosed and undergone proteolysis and therby localization of VE-cadherin at the plasma membrane is lost. As a result of destabilization of EphA2 and VE-cadherin at the plasma membrane in lung vascular endothelial cells leads to hyper-permeability and enhances lung metastasis. A neutralizing antibody against ephrin-A1 is effective for lung metastasis. I would like to develop anti-ephrin-A1 therapeutic drugs.
|
